Royalty Pharma Plc Net Income
| RPRX Stock | USD 44.65 0.55 1.25% |
As of the 9th of February, Royalty Pharma holds the Coefficient Of Variation of 549.09, semi deviation of 1.31, and Risk Adjusted Performance of 0.1516. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Royalty Pharma, as well as the relationship between them.
Royalty Pharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 11.1527 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.5 B | 1.1 B | |
| Net Income Applicable To Common Shares | 49.3 M | 46.8 M | |
| Net Income | 1.5 B | 1.1 B | |
| Net Income Per Share | 2.21 | 2.68 | |
| Net Income Per E B T | 0.74 | 0.75 |
Royalty | Net Income | Build AI portfolio with Royalty Stock |
The evolution of Net Income for Royalty Pharma Plc provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Royalty Pharma compares to historical norms and industry peers.
Latest Royalty Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Royalty Pharma Plc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Royalty Pharma Plc financial statement analysis. It represents the amount of money remaining after all of Royalty Pharma Plc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Royalty Pharma's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.33 B | 10 Years Trend |
|
Net Income |
| Timeline |
Royalty Net Income Regression Statistics
| Arithmetic Mean | 676,967,344 | |
| Coefficient Of Variation | 97.89 | |
| Mean Deviation | 522,998,600 | |
| Median | 619,728,000 | |
| Standard Deviation | 662,678,786 | |
| Sample Variance | 439143.2T | |
| Range | 2.4B | |
| R-Value | 0.54 | |
| Mean Square Error | 333755T | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | 70,362,609 | |
| Total Sum of Squares | 7026290.8T |
Royalty Net Income History
Other Fundumenentals of Royalty Pharma Plc
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Royalty Pharma Net Income component correlations
Royalty Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Royalty Pharma is extremely important. It helps to project a fair market value of Royalty Stock properly, considering its historical fundamentals such as Net Income. Since Royalty Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Royalty Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Royalty Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. Anticipated expansion of Royalty directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Royalty Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.45) | Dividend Share 0.87 | Earnings Share 1.75 | Revenue Per Share | Quarterly Revenue Growth 0.079 |
Understanding Royalty Pharma Plc requires distinguishing between market price and book value, where the latter reflects Royalty's accounting equity. The concept of intrinsic value - what Royalty Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Royalty Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Royalty Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Royalty Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Royalty Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Royalty Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Royalty Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Royalty Pharma.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Royalty Pharma on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Royalty Pharma Plc or generate 0.0% return on investment in Royalty Pharma over 90 days. Royalty Pharma is related to or competes with Genmab AS, United Therapeutics, Incyte, Fresenius Medical, Summit Therapeutics, Smith Nephew, and Roivant Sciences. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutic... More
Royalty Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Royalty Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Royalty Pharma Plc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.58 | |||
| Information Ratio | 0.1248 | |||
| Maximum Drawdown | 12.26 | |||
| Value At Risk | (2.05) | |||
| Potential Upside | 2.03 |
Royalty Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Royalty Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Royalty Pharma's standard deviation. In reality, there are many statistical measures that can use Royalty Pharma historical prices to predict the future Royalty Pharma's volatility.| Risk Adjusted Performance | 0.1516 | |||
| Jensen Alpha | 0.2388 | |||
| Total Risk Alpha | 0.1202 | |||
| Sortino Ratio | 0.1239 | |||
| Treynor Ratio | 0.6068 |
Royalty Pharma February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1516 | |||
| Market Risk Adjusted Performance | 0.6168 | |||
| Mean Deviation | 1.08 | |||
| Semi Deviation | 1.31 | |||
| Downside Deviation | 1.58 | |||
| Coefficient Of Variation | 549.09 | |||
| Standard Deviation | 1.56 | |||
| Variance | 2.45 | |||
| Information Ratio | 0.1248 | |||
| Jensen Alpha | 0.2388 | |||
| Total Risk Alpha | 0.1202 | |||
| Sortino Ratio | 0.1239 | |||
| Treynor Ratio | 0.6068 | |||
| Maximum Drawdown | 12.26 | |||
| Value At Risk | (2.05) | |||
| Potential Upside | 2.03 | |||
| Downside Variance | 2.48 | |||
| Semi Variance | 1.71 | |||
| Expected Short fall | (1.21) | |||
| Skewness | 0.1967 | |||
| Kurtosis | 5.92 |
Royalty Pharma Plc Backtested Returns
Royalty Pharma appears to be very steady, given 3 months investment horizon. Royalty Pharma Plc maintains Sharpe Ratio (i.e., Efficiency) of 0.2, which implies the firm had a 0.2 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Royalty Pharma Plc, which you can use to evaluate the volatility of the company. Please evaluate Royalty Pharma's Coefficient Of Variation of 549.09, semi deviation of 1.31, and Risk Adjusted Performance of 0.1516 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Royalty Pharma holds a performance score of 15. The company holds a Beta of 0.45, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Royalty Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Royalty Pharma is expected to be smaller as well. Please check Royalty Pharma's maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to make a quick decision on whether Royalty Pharma's historical price patterns will revert.
Auto-correlation | -0.45 |
Modest reverse predictability
Royalty Pharma Plc has modest reverse predictability. Overlapping area represents the amount of predictability between Royalty Pharma time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Royalty Pharma Plc price movement. The serial correlation of -0.45 indicates that just about 45.0% of current Royalty Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.45 | |
| Spearman Rank Test | -0.31 | |
| Residual Average | 0.0 | |
| Price Variance | 2.83 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Royalty Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Royalty Pharma Plc reported net income of 1.33 B. This is 289.94% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 133.08% lower than that of the firm.
Royalty Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Royalty Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Royalty Pharma could also be used in its relative valuation, which is a method of valuing Royalty Pharma by comparing valuation metrics of similar companies.Royalty Pharma is currently under evaluation in net income category among its peers.
Royalty Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Royalty Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Royalty Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Royalty Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Royalty Pharma's value.| Shares | Norges Bank | 2025-06-30 | 5 M | Victory Capital Management Inc. | 2025-06-30 | 4.5 M | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 4.1 M | Northern Trust Corp | 2025-06-30 | 4 M | Charles Schwab Investment Management Inc | 2025-06-30 | 3 M | Patients Capital Management Llc | 2025-06-30 | 3 M | Arrowstreet Capital Limited Partnership | 2025-06-30 | 3 M | Newsouth Capital Management Inc | 2025-06-30 | 2.9 M | Amundi | 2025-06-30 | 2.8 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 46.6 M | Fmr Inc | 2025-06-30 | 40.4 M |
Royalty Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0522 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.70 % | ||||
| Current Valuation | 26.21 B | ||||
| Shares Outstanding | 427.25 M | ||||
| Shares Owned By Insiders | 8.83 % | ||||
| Shares Owned By Institutions | 82.00 % | ||||
| Number Of Shares Shorted | 27.51 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 2.97 X | ||||
| Price To Sales | 11.08 X | ||||
| Revenue | 2.26 B | ||||
| Gross Profit | 2.5 B | ||||
| EBITDA | 1.56 B | ||||
| Net Income | 1.33 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 7.61 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 14.95 X | ||||
| Cash Flow From Operations | 2.77 B | ||||
| Short Ratio | 7.48 X | ||||
| Earnings Per Share | 1.75 X | ||||
| Price To Earnings To Growth | 1.97 X | ||||
| Target Price | 48.1 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 26.04 B | ||||
| Total Asset | 18.22 B | ||||
| Retained Earnings | 2.85 B | ||||
| Working Capital | 548.52 M | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 18.22 B | ||||
| Last Dividend Paid | 0.87 |
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.